Microangiopathic hemolytic anemia natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
MydahSajid (talk | contribs) No edit summary |
MydahSajid (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
* If left untreated, 90% of [[patient]]s with [[[microangiopathic hemolytic anemia]] may die<ref name="pmid2062330">{{cite journal| author=Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC | display-authors=etal| title=Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. | journal=N Engl J Med | year= 1991 | volume= 325 | issue= 6 | pages= 393-7 | pmid=2062330 | doi=10.1056/NEJM199108083250604 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2062330 }} </ref>. | * If left untreated, 90% of [[patient]]s with [[[microangiopathic hemolytic anemia]] may die<ref name="pmid2062330">{{cite journal| author=Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC | display-authors=etal| title=Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. | journal=N Engl J Med | year= 1991 | volume= 325 | issue= 6 | pages= 393-7 | pmid=2062330 | doi=10.1056/NEJM199108083250604 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2062330 }} </ref>. | ||
* The prognosis can be improved with prompt treatment. Therapeutic [[plasmapheresis]] reduces mortality rate to 20%<ref name="pmid2062330">{{cite journal| author=Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC | display-authors=etal| title=Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. | journal=N Engl J Med | year= 1991 | volume= 325 | issue= 6 | pages= 393-7 | pmid=2062330 | doi=10.1056/NEJM199108083250604 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2062330 }} </ref>. | * The prognosis can be improved with prompt treatment. Therapeutic [[plasmapheresis]] reduces mortality rate to 20%<ref name="pmid2062330">{{cite journal| author=Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC | display-authors=etal| title=Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. | journal=N Engl J Med | year= 1991 | volume= 325 | issue= 6 | pages= 393-7 | pmid=2062330 | doi=10.1056/NEJM199108083250604 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2062330 }} </ref>. | ||
== | * Common complications of [[microangiopathic hemolytic anemia]] include [acute renal failure] with raised [[serum]] [[urea]] and [[creatinine]] levels, [[intracranial hemorrhage]], and [[myocardial infarction]] due to [[coronary artery]] occlusion<ref name="ScullyHunt2012">{{cite journal|last1=Scully|first1=Marie|last2=Hunt|first2=Beverley J.|last3=Benjamin|first3=Sylvia|last4=Liesner|first4=Ri|last5=Rose|first5=Peter|last6=Peyvandi|first6=Flora|last7=Cheung|first7=Betty|last8=Machin|first8=Samuel J.|title=Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies|journal=British Journal of Haematology|volume=158|issue=3|year=2012|pages=323–335|issn=00071048|doi=10.1111/j.1365-2141.2012.09167.x}}</ref> | ||
. | |||
==Reference== | |||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 15:10, 30 January 2021
|
Microangiopathic hemolytic anemia Microchapters |
|
Differentiating Microangiopathic hemolytic anemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Microangiopathic hemolytic anemia natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Microangiopathic hemolytic anemia natural history, complications and prognosis |
|
FDA on Microangiopathic hemolytic anemia natural history, complications and prognosis |
|
on Microangiopathic hemolytic anemia natural history, complications and prognosis |
|
Microangiopathic hemolytic anemia natural history, complications and prognosis in the news |
|
Blogs on Microangiopathic hemolytic anemia natural history, complications and prognosis |
|
Directions to Hospitals Treating Microangiopathic hemolytic anemia |
- If left untreated, 90% of patients with [[[microangiopathic hemolytic anemia]] may die[1].
- The prognosis can be improved with prompt treatment. Therapeutic plasmapheresis reduces mortality rate to 20%[1].
- Common complications of microangiopathic hemolytic anemia include [acute renal failure] with raised serum urea and creatinine levels, intracranial hemorrhage, and myocardial infarction due to coronary artery occlusion[2]
.
Reference
- ↑ 1.0 1.1 Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC; et al. (1991). "Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group". N Engl J Med. 325 (6): 393–7. doi:10.1056/NEJM199108083250604. PMID 2062330.
- ↑ Scully, Marie; Hunt, Beverley J.; Benjamin, Sylvia; Liesner, Ri; Rose, Peter; Peyvandi, Flora; Cheung, Betty; Machin, Samuel J. (2012). "Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies". British Journal of Haematology. 158 (3): 323–335. doi:10.1111/j.1365-2141.2012.09167.x. ISSN 0007-1048.